Top

Published in:

01-01-2011

The Role of Medical Imaging in Defining CNS Abnormalities Associated with HIV-Infection and Opportunistic Infections

Authors: David F. Tate, Ph.D., Rola Khedraki, Daniel McCaffrey, Daniel Branson, Jeffrey Dewey

Published in: Neurotherapeutics | Issue 1/2011

Summary

In this review of the current literature, we examine the role of medical imaging in providing new and relevant information on central nervous system (CNS) injury associated with human immunodeficiency virus (HIV) infection and various clinical manifestations of this injury. Common imaging modalities used to examine CNS injury in HIV infection include structural magnetic resonance imaging, magnetic resonance spectroscopy, diffusion tensor imaging, functional MRI, and positron emissions tomography. Clinical implications for the findings are discussed for each of these modalities individually and collectively. In addition, the direction for future studies is suggested in an attempt to provide possible methods that might answer the many questions that remain to be answered on the evolution and progression of CNS injury in the context of HIV infection.

Available only for authorised users

Sacktor N, McDermott M, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136–142.PubMed

McArthur J, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003;9:205–221.PubMed

McCutchan JA, Wu JW, Robertson K, et al. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007;21:1109–1117.PubMed

Aylward EH, Henderer JD, McArthur JC, et al. Reduced basal ganglia volume in HIV-1-associated dementia: Results from quantitative neuroimaging. Neurology 1993;43:2099–2104.PubMed

Dal Pan GJ, McArthur JH, Aylward E, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology 1992;42:2125–2130.PubMed

Hestad K, McArthur JH, Pan GJD, et al. Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol Scand 1993;88:112–118.PubMed

Broderick D, Wippold F, Clifford D, Kido D, Wilson B. White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex. Am J Roentgenol 1993;161:177–181.

Olsen WL, Longo FM, Mills CM, Norman D. White matter disease in AIDS: findings at MR imaging. Radiology 1988;169:445–448.PubMed

Jakobsen J, Gyldensted C, Brun B, Bruhn P, Helweg-Larsen S, Arlien-Søborg P. Cerebral ventricular enlargement relates to neuropsychological measures in unselected AIDS patients. Acta Neurol Scand 1989;79:59–62.PubMed

10.

Elovaara I, Poutiainen E, Raininko R, et al. Mild brain atrophy in early HIV infection: the lack of association with cognitive deficits and HIV-specific intrathecal immune response. J Neurol Sci 1990;99:121–136.PubMed

11.

Everall IP, Chong WK, Wilkinson ID, et al. Correlation of MRI and neuropathology in AIDS. J Neurol Neurosurg Psychiatry 1997;62:92–95.PubMed

12.

Harrison MJG, Newman SP, Hall-Craggs MA, et al. Evidence of CNS impairment in HIV infection: clinical, neuropsychological, EEG, and MRI/MRS study. J Neurol Neurosurg Psychiatry 1998;65:301–307.PubMed

13.

Archibald SL, Masliah E, Fennema-Notestine C, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol 2004;61:369–376.PubMed

14.

Aylward EH, Brettschneider PD, McArthur JC, et al. Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am J Psychiatry 1995;152:987–994.PubMed

15.

Paul R, Cohen R, Navia B, Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci Biobehav Rev 2002;26:353–359.PubMed

16.

Chiang M-C, Dutton RA, Hayashi KM, et al. 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. NeuroImage 2007;34:44–60.PubMed

17.

Stout JC, Ellis RJ, Jernigan TL, et al. Progressive cerebral volume loss in human immunodeficiency virus infection: A longitudinal volumetric magnetic resonance imaging study. Arch Neurol 1998;55:161–168.PubMed

18.

Di Sclafani V, Mackay RD, Meyerhoff DJ, Norman D, Weiner MW, Fein G. Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment. J Int Neuropsychol Soc 1997;3:276–287.PubMed

19.

Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005;162:1461–1472.PubMed

20.

Kieburtz K, Ketonen L, Cox C, et al. Cognitive Performance and Regional Brain Volume in Human Immunodeficiency Virus Type 1 Infection. Arch Neurol 1996;53:155–158.PubMed

21.

Price RW, Epstein LG, Becker JT, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology 2007;69:1781–1788.PubMed

22.

Brew B, Rosenbloom M, Cronin K, Price R. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol 1995;38:563–570.PubMed

23.

Neuen Jacob E, Arendt G, Wendtland B, Jacob B, Schneeweis M, Wechsler W. Frequency and topographical distribution of CD68-positive macrophages and HIV-1 core proteins in HIV-associated brain lesions. Clin Neuropathol 1993;12:315–324.PubMed

24.

Hawkins CP, McLaughlin JE, Kendall BE, McDonald WI. Pathological findings correlated with MRI in HIV infection. Neuroradiology 1993;35:264–268.PubMed

25.

Avison M, Nath A, Greeneavison R, Schmitt F, Greenberg R, Berger J. Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol 2004;157:140–146.PubMed

26.

Berger JR, Nath A, Greenberg RN, et al. Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 2000;54:921–926.PubMed

27.

McMurtray A, Nakamoto B, Shikuma C, Valcour V. Cortical atrophy and white matter hyperintensities in HIV: the Hawaii Aging with HIV Cohort Study. J Stroke Cerebrovasc Dis 2008;17:212–217.PubMed

28.

Thompson P, Dutton R, Hayashi K, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 2005;102:15647.PubMed

29.

Thompson PM, Dutton RA, Hayashi KM, et al. 3D mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. NeuroImage 2006;31:12–23.PubMed

30.

Laissy J, Patrux B, Duchateau C, et al. Midsagittal MR measurements of the corpus callosum in healthy subjects and diseased patients: a prospective survey. AJNR Am J Neuroradiol 1993;14:145–154.PubMed

31.

Wohlschlaeger J, Wenger E, Mehraein P, Weis S. White matter changes in HIV-1 infected brains: a combined gross anatomical and ultrastructural morphometric investigation of the corpus callosum. Clin Neurol Neurosurg 2009;111:422–429.PubMed

32.

Tate DF, Harezlak J, Dewey J, et al. Mapping HIV disease to the corpus callosum: cross sectional and longitudinal analyses. Presented at Human Brain Mapping 2010; Barcelona, Spain.

33.

Ge Y, Kolson DL, Babb JS, Mannon LJ, Grossman RI. Whole brain imaging of HIV-infected patients: Quantitative analysis of magnetization transfer ratio histogram and fractional brain volume. AJNR Am J Neuroradiol 2003;24:82–87.PubMed

34.

Paley MN, Chong WK, Wilkinson ID, et al. Cerebrospinal fluid-intracranial volume ratio measurements in patients with HIV infection: CLASS image analysis technique. Radiology 1994;190:879–886.PubMed

35.

Wang Y, Zhang J, Gutman B, et al. Multivariate tensor-based morphometry on surfaces: Application to mapping ventricular abnormalities in HIV/AIDS. NeuroImage 2010;49:2141–2157.PubMed

36.

Pfefferbaum A, Rosenbloom MJ, Rohlfing T, et al. Contribution of alcoholism to brain dysmorphology in HIV infection: effects on the ventricles and corpus callosum. Neuroimage 2006;33:239–251.PubMed

37.

Patel SH, Kolson DL, Glosser G, et al. Correlation between percentage of brain parenchymal volume and neurocognitive performance in HIV-infected patients. AJNR Am J Neuroradiol 2002;23:543–549.PubMed

38.

Castelo JMB, Courtney MG, Melrose RJ, Stern CE. Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise. Arch Neurol 2007;64:1275–1280.PubMed

39.

Cardenas V, Meyerhoff D, Studholme C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 2009;15:324–33.PubMed

40.

Pomara N, Crandall DT, Choi SJ, Johnson G, Lim KO. White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res 2001;106:15–24.PubMed

41.

Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR. Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 2004;25:195–200.PubMed

42.

Smith C, Stebbins G, Bartt R, et al. Gender effects on HIV-associated white matter alterations: a voxel-wise DTI study. Brain Imaging Behav 2008;2:177–191.

43.

Filippi M, Dousset V, McFarland HF, Miller DH, Grossman RI. Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. J Magn Reson Imaging 2002;15:499–504.PubMed

44.

Thurnher MM, Castillo M, Stadler A, Rieger A, Schmid B, Sundgren PC. Diffusion-tensor MR imaging of the brain in human immunodeficiency virus-positive patients. AJNR Am J Neuroradiol 2005;26:2275–2281.PubMed

45.

Ragin AB, Storey P, Cohen BA, Edelman RR, Epstein LG. Disease burden in HIV-associated cognitive impairment: a study of whole-brain imaging measures. Neurology 2004;63:2293–2297.PubMed

46.

Ragin AB, Wu Y, Storey P, Cohen BA, Edelman RR, Epstein LG. Diffusion tensor imaging of subcortical brain injury in patients infected with human immunodeficiency virus. J Neurovirol 2005;11:292–298.PubMed

47.

Wu Y, Storey P, Cohen BA, Epstein LG, Edelman RR, Ragin AB. Diffusion alterations in corpus callosum of patients with HIV. AJNR Am J Neuroradiol 2006;27:656–660.PubMed

48.

Tate DF, Conley J, Paul RH, et al. Quantitative Diffusion Tensor Imaging Tractography Metrics Are Associated with Cognitive Performance Among HIV-Infected Patients. Brain Imaging Behav 2010;4:68–79.PubMed

49.

Pfefferbaum A, Rosenbloom MJ, Adalsteinsson E, Sullivan EV. Diffusion tensor imaging with quantitative fibre tracking in HIV infection and alcoholism comorbidity: synergistic white matter damage. Brain 2007;130:48–64.PubMed

50.

Pfefferbaum A, Rosenbloom MJ, Rohlfing T, Kemper CA, Deresinski S, Sullivan EV. Frontostriatal fiber bundle compromise in HIV infection without dementia. AIDS 2009;23:1977–1985.PubMed

51.

Chen Y, An H, Zhu H, et al. White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients. Neuroimage 2009;47:1154–1162.PubMed

52.

Bottomley PA, Hardy CJ, Cousins JP, Armstrong M, Wagle WA. AIDS dementia complex: brain high-energy phosphate metabolite deficits. Radiology 1990;176:407–411.PubMed

53.

Deicken RF, Hubesch B, Jensen PC, et al. Alterations in brain phosphate metabolite concentrations in patients with human immunodeficiency virus infection. Arch Neurol 1991;48:203–209.PubMed

54.

Meyerhoff DJ, MacKay S, Bachman L, et al. Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: In vivo 1 H magnetic resonance spectroscopic imaging. Neurology 1993;43:509–515.PubMed

55.

Paley M, Wilkinson ID, Hall-Craggs MA, Chong WK, Chinn RJ, Harrison MJ. Short echo time proton spectroscopy of the brain in HIV infection/AIDS. Magn Reson Imaging 1995;13:871–875.PubMed

56.

Jarvik JG, Lenkinski RE, Grossman RI, Gomori JM, Schnall MD, Frank I. Proton MR spectroscopy of HIV-infected patients: characterization of abnormalities with imaging and clinical correlation. Radiology 1993;186:739–744.PubMed

57.

Weller IV, Chong WK, Sweeney B, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology 1993;188:119–124.PubMed

58.

Vion-Dury J, Salvan AM, Confort-Gouny S, Cozzone PJ. Brain proton magnetic resonance spectroscopy. Indications for diagnosis and follow-up of HIV-related encephalopathy in the adult. Presse Médicale (Paris, France: 1983) 1998;27:1398.

59.

Tarasow E, Wiercin’ ska-Drapa o A, Kubas B, et al. Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients. Acta Radiol 2003;44:206–212.PubMed

60.

Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 2005;162:361–369.PubMed

61.

Paul RH, Yiannoutsos CT, Miller EN, et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 2007;19:283–292.PubMed

62.

Westmoreland S, Ratai EM, Pilkenton S, et al. In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain. BMC Neurosci 2009;10:63.PubMed

63.

Barker PB, Lee RR, McArthur JC. AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology 1995;195:58–64.PubMed

64.

Laubenberger J, Häussinger D, Bayer S, et al. HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 1996;199:805–810.PubMed

65.

Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: A proton magnetic resonance spectroscopic study. Neurology 1996;46:783–788.PubMed

66.

Salvan A, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy: comparison between sequences using short and long echo times. Invest Radiol 1997;32:485–495.PubMed

67.

Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999;52:100–108.PubMed

68.

Lee PL, Yiannoutsos CT, Ernst T, et al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging 2003;17:625–633.PubMed

69.

Chang L, Ernst T, Leonido-Yee M, et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia. Neurology 1999;53:782–789.PubMed

70.

Salvan AM, Lamoureux S, Michel G, Confort-Gouny S, Cozzone PJ, Vion-Dury J. Localized proton magnetic resonance spectroscopy of the brain in children infected with human immunodeficiency virus with and without encephalopathy. Pediatr Res 1998;44:755–62.PubMed

71.

Bricaire F, Stankoff B, Tourbah A, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 2001;56:112.PubMed

72.

Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage 2002;17:1638–1648.PubMed

73.

Chang L, Tomasi D, Yakupov R, et al. Adaptation of the attention network in human immunodeficiency virus brain injury. Ann Neurol 2004;56:259–272.PubMed

74.

Tucker KA, Robertson KR, Lin W, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004;157:153–162.PubMed

75.

Lentz MR, Kim WK, Lee V, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009;72:1465–1472.PubMed

76.

Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999;20:1619–27.PubMed

77.

Behar KL, Boucher R, Fritch W, Manuelidis L. Changes in N-acetylaspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeldt-Jakob disease. Magn Reson Imaging 1998;16:963–968.PubMed

78.

Castelo JMB, Sherman SJ, Courtney MG, Melrose RJ, Stern CE. Altered hippocampal-prefrontal activation in HIV patients during episodic memory encoding. Neurology 2006;66:1688–1695.PubMed

79.

Chang L, Speck O, Miller EN, et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology 2001;57:1001–1007.PubMed

80.

Melrose RJ, Tinaz S, Castelo JMB, Courtney MG, Stern CE. Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res 2008;188:337–347.PubMed

81.

Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002;59:1343–1349.PubMed

82.

Andersen A, Law I, Krabbe K, et al. Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation 2010;7:13.PubMed

83.

Georgiou MF, Gonenc A, Waldrop-Valverde D, et al. Analysis of the effects of injecting drug use and HIV-1 infection on 18F-FDG PET brain metabolism. J Nucl Med 2008;49:1999–2005.PubMed

84.

von Giesen H-J, Antke C, Hefter H, Wenserski F, Seitz RJ, Arendt G. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch Neurol 2000;57:1601–1607.

85.

Hinkin C, van Gorp W, Mandelkern M, et al. Cerebral metabolic change in patients with AIDS: report of a six-month follow-up using positron-emission tomography. J Neuropsychiatry Clin Neurosci 1995;7:180–187.PubMed

86.

Chang L, Wong V, Nakama H, et al. Greater than age-related changes in brain diffusion of HIV patients after 1 year. J Neuroimmune Pharmacol 2008;3:265–274.PubMed

87.

Wang G-J, Chang L, Volkow ND, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 2004;127:2452–2458.PubMed

88.

Hammoud DA, Endres CJ, Chander AR, et al. Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol 2005;11:346–355.PubMed

89.

Rosci M, Pigorini F, Bernebei A. Methods for detecting early signs of AIDS dementia complex in asymptomatic HIV-1-infected patients. AIDS 1992;6:1309–1316.PubMed

90.

Modi M, Mochan A, Modi G. Management of HIV-associated focal brain lesions in developing countries. Q J Med 2004;97:413–421.

91.

Ernst T, Itti E, Itti L, Chang L. Changes in cerebral metabolism are detected prior to perfusion changes in early HIV-CMC: a coregistered (1)H MRS and SPECT study. J Magn Reson Imaging 2000;12:859–865.PubMed

92.

Sacktor N, Van Heertum R, Dooneief G, al e. A comparison of cerebral SPECT abnormalities in HIV-positive homosexual men with and without cognitive impairment. Arch Neurol 1995;52:1170–1173.PubMed

93.

Giancola ML, Rizzi EB, Schiavo R, et al. Reduced value of thallium-201 single-photon emission computed tomography in the management of HIV-related focal brain lesions in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:584–588.PubMed

94.

Chang L, Ernst T, Leonido-Yee M, Speck O. Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex. Neurology 2000;54:389–396.PubMed

95.

Wenserski F, von Giesen HJ, Wittsack HJ, Aulich A, Arendt G. Human immunodeficiency virus 1-associated minor motor disorders: perfusion-weighted MR imaging and H MR spectroscopy. Radiology 2003;228:185–192.PubMed

96.

Ances B, Ellis R. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007: 27: 86–92..PubMed

97.

Kucharczyk W, Macdonald PM, Stanisz GJ, Henkelman RM. Relaxivity and magnetization transfer of white matter lipids at MR imaging: importance of cerebrosides and pH. Radiology 1994;192:521-529.PubMed

98.

Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 2005;193:218–227.PubMed

99.

Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211–222.PubMed

100.

Post MJ, Sheldon JJ, Hensley GT, et al. Central nervous system disease in acquired immunodeficiency syndrome: prospective correlation using CT, MR imaging, and pathologic studies. Radiology 1986;158:141–148.PubMed

101.

Levy RM, Mills CM, Posin JP, Moore SG, Rosenblum ML, Bredesen DE. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr 1990;3:461–471.PubMed

102.

Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990;73:720–724.PubMed

103.

Ho Y-C, Sun H-Y, Chen M-Y, Hsieh S-M, Sheng W-H, Chang S-C. Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection. J Microbiol Immunol Infect 2008;41:386–392.PubMed

104.

Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:103–15.PubMed

105.

Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837–842.PubMed

106.

Berkefeld J, Enzensberger W, Lanfermann H. Cryptococcus meningoencephalitis in AIDS: parenchymal and meningeal forms. Neuroradiology 1999;41:129–133.PubMed

107.

Narai H, Manabe Y, Deguchi K, Iwatsuki K, Sakai K, Abe K. Serial MRI findings in patient with chronic Cryptococcus meningo-enchephalitis. Neurol Res 2001;23:810–812.

108.

Kovoor JME, Mahadevan A, Narayan JP, et al. Cryptococcal Choroid Plexitis as a Mass Lesion: MR Imaging and Histopathologic Correlation. AJNR Am J Neuroradiol 2002;23:273–276.PubMed

109.

Wehn SM, Heinz ER, Burger PC, Boyko OB. Dilated Virchow-Robin spaces in cryptococcal meningitis associated with AIDS: CT and MR findings. J Computer Assist Tomogr 1989;13:756–762.PubMed

110.

Groeschel S, Chong W, Surtees R, Hanefeld F. Virchow-Robin spaces on magnetic resonance images: normative data, their dilatation, and a review of the literature. Neuroradiology 2006;48:745–754.PubMed

111.

Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9:47–53.PubMed

112.

Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001;56:257–260.PubMed

113.

Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:1257–1260.PubMed

114.

Guilleux MH, Steiner RE, Young IR. MR imaging in progressive multifocal leukoencephalopathy. AJNR Am J Neuroradiol 1986;7:1033–1035.PubMed

115.

Mark AS, Atlas SW. Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images. Radiology 1989;173:517–520.PubMed

116.

Wheeler AL, Truwit CL, Kleinschmidt-DeMasters BK, Byrne WR, Hannon RN. Progressive multifocal leukoencephalopathy: contrast enhancement on CT scans and MR images. Am J Roentgenol 1993;161:1049–1051.

117.

Thurnher MM, Donovan Post MJ, Rieger A, Kleibl-Popov C, Loewe C, Schindler E. Initial and Follow-up MR Imaging Findings in AIDS-Related Progressive Multifocal Leukoencephalopathy Treated with Highly Active Antiretroviral Therapy. AJNR Am J Neuroradiol 2001;22:977–984.PubMed

118.

Giancola ML, Rizzi EB, Lorenzini P, et al. Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables. AIDS Res Hum Retroviruses 2008;24:155–162.PubMed

119.

Pfefferbaum A, Rosenbloom M, Sullivan EV. Alcoholism and AIDS: magnetic resonance imaging approaches for detecting interactive neuropathology. Alcohol Clin Exp Res 2002;26:1031–1046.PubMed

120.

Chang L, Ernst T, St Hillaire C, Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antiviral therapy 2004;9:431–440.PubMed

121.

Martin EM, Novak RM, Fendrich M, et al. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc 2004;10:298–300.PubMed

122.

Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002;59:1563–1567.PubMed

123.

Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007;196:361–370.PubMed

124.

Sampat MP, Healy BC, Meier DS, Dell’Oglio E, Liguori M, Guttmann CR. Disease modeling in multiple sclerosis: assessment and quantification of sources of variability in brain parenchymal fraction measurements. NeuroImage 2010;52:1367–1373.PubMed

125.

Barnes J, Boyes RG, Lewis EB, et al. Automatic calculation of hippocampal atrophy rates using a hippocampal template and the boundary shift integral. Neurobiol Aging 2007;28:1657–1663.PubMed

126.

Barnes J, Godbolt AK, Frost C, et al. Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiol Aging 2007;28:20–28.PubMed

127.

Bradley KM, Bydder GM, Budge MM, et al. Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer’s disease. Br J Radiol 2002;75:506–513.PubMed

Title: The Role of Medical Imaging in Defining CNS Abnormalities Associated with HIV-Infection and Opportunistic Infections
Authors: David F. Tate, Ph.D.
Rola Khedraki
Daniel McCaffrey
Daniel Branson
Jeffrey Dewey
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Neurotherapeutics / Issue 1/2011
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-010-0010-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Medical Imaging in Defining CNS Abnormalities Associated with HIV-Infection and Opportunistic Infections

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2011

Transitions and Transformations

Neuroimaging in Psychiatric Disorders

Fourth Annual Huntington Disease Clinical Research Symposium

Neuroimaging in Parkinson’s Disease

Neuroimaging of Hemorrhage and Vascular Defects

Neuroimaging in Multiple Sclerosis: Neurotherapeutic Implications